China Biologic Products (NASDAQ: CBPO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare China Biologic Products to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, dividends, valuation and earnings.

Insider & Institutional Ownership

65.7% of China Biologic Products shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares China Biologic Products and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
China Biologic Products 31.29% 21.49% 18.58%
China Biologic Products Competitors -5,355.33% -433.53% -38.99%

Analyst Recommendations

This is a breakdown of current recommendations for China Biologic Products and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China Biologic Products 0 1 2 0 2.67
China Biologic Products Competitors 845 3193 11580 230 2.71

China Biologic Products currently has a consensus target price of $137.50, indicating a potential upside of 69.11%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.21%. Given China Biologic Products’ higher possible upside, analysts plainly believe China Biologic Products is more favorable than its competitors.

Earnings & Valuation

This table compares China Biologic Products and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
China Biologic Products $341.17 million $104.77 million 20.48
China Biologic Products Competitors $284.30 million $34.29 million 129.99

China Biologic Products has higher revenue and earnings than its competitors. China Biologic Products is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

China Biologic Products has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, China Biologic Products’ competitors have a beta of 1.80, indicating that their average share price is 80% more volatile than the S&P 500.

Summary

China Biologic Products beats its competitors on 7 of the 13 factors compared.

About China Biologic Products

China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Receive News & Ratings for China Biologic Products Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.